Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Dec 10;12:4181–4189. doi: 10.2147/DDDT.S181312

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 Jiang et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

ADAR1 affects cell tube branching formation and permeability through FGFR2 during proliferation.

Notes: (A) Cell apoptosis rates detected by flow cytometry comparing treatment of FGF2 or vector in sh-ADAR1 cells. (B) Cell proliferation analysis using MTS assay under FGF2 treatment. (C) Knocking down of ADAR1 by two shRNAs increases cellular caspase-3 activity. (D) Western blot analysis of cell apoptosis related protein in sh-ADAR1 cells as well as rescued cells by FGF2. (E) Cell permeability measurement after FGF2 treatment. (F) Matrigel tube formation assay in the condition of ADAR1 inhibition with or without FGF2 treatment. Values are expressed as mean ± SE. *P<0.05, as compared to the control; ^#P<0.05, as compared to sh-ADAR1.

Abbreviations: ADAR1, adenosine deaminase acting on RNA 1; FGFR2, fibroblast growth factor receptor 2; HUVEC, human umbilical vein endothelial cell; NC, negative control.